| Non-Hodgkin Lymphoma (NHL) |
1 |
1 |
| Diffuse Large Cell Lymphoma |
0 |
0.95 |
| Lymphoma |
0 |
0.63 |
| B-Cell Lymphoma |
0 |
0.95 |
| Hodgkin Lymphoma |
0 |
0.51 |
| Follicular Lymphoma |
0 |
0.49 |
| Mantle Cell Lymphoma |
0 |
0.47 |
| CNS Lymphoma |
0 |
0.43 |
| Biologic Therapy |
0 |
0.41 |
| Monoclonal Antibody |
0 |
0.29 |
| Antineoplastic Drug |
0 |
0.27 |
| Refractory |
0 |
0.23 |
| Heart Failure (HF) |
0 |
0.2 |
| Neutropenia |
0 |
0.17 |
| Renal Failure |
0 |
0.13 |
| Stem Cell Research and Therapy |
0 |
0.13 |
| Heart |
0 |
0.12 |
| Acute Kidney Injury |
0 |
0.06 |
| Adenocarcinoma |
0 |
0.06 |
| Antigens |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Cardiac Arrest |
0 |
0.06 |
| Central Nervous System |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Hematology |
0 |
0.06 |
| Leukopenia |
0 |
0.06 |
| Lung |
0 |
0.06 |
| Lymphocytes |
0 |
0.06 |
| Prognosis |
0 |
0.06 |
| Respiratory Failure |
0 |
0.06 |
| Texas |
0 |
0.06 |
| Transplantation |
0 |
0.06 |